Rapport d’analyse de la taille, de la part et des tendances du marché mondial des tumeurs stromales gastro-intestinales – Aperçu et prévisions de l’industrie jusqu’en 2031

Analyse du marché des tumeurs stromales gastro-intestinales

Le marché des tumeurs stromales gastro-intestinales (GIST) connaît une croissance notable, tirée par les progrès des options de diagnostic et de traitement. Les GIST, qui sont des tumeurs rares issues des cellules interstitielles de Cajal dans le tractus gastro-intestinal, ont connu une sensibilisation accrue et des méthodes de détection améliorées, permettant un diagnostic plus précoce et de meilleurs résultats pour les patients. Les développements récents dans les thérapies ciblées, en particulier l'approbation de nouveaux inhibiteurs de la tyrosine kinase, ont transformé le paysage thérapeutique des patients atteints de GIST. Par exemple, l'introduction de médicaments tels que l'Imatinib et le Sunitinib a considérablement amélioré les taux de survie et la qualité de vie des personnes diagnostiquées avec des GIST avancés. De plus, les recherches en cours sur les thérapies de nouvelle génération et les traitements combinés devraient encore améliorer l'efficacité du traitement. En outre, l'augmentation des essais cliniques axés sur la médecine personnalisée met en évidence le potentiel des thérapies sur mesure basées sur le profilage génétique, ouvrant la voie à des approches thérapeutiques innovantes. Alors que le marché des GIST continue d'évoluer, l'accent mis sur les soins multidisciplinaires et les stratégies centrées sur le patient devient de plus en plus important, promettant un avenir meilleur aux patients confrontés à ce diagnostic difficile.

Taille du marché des tumeurs stromales gastro-intestinales

Français La taille du marché mondial des tumeurs stromales gastro-intestinales a été évaluée à 1,21 milliard USD en 2023 et devrait atteindre 2,02 milliards USD d'ici 2031, avec un TCAC de 6,60 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Tendances du marché des tumeurs stromales gastro-intestinales

« Adoption croissante de la médecine personnalisée »

The gastrointestinal stromal tumor (GIST) market is experiencing notable growth driven by advancements in targeted therapies and increasing awareness of rare tumors. A key trend in this market is the rising adoption of personalized medicine, which tailors treatment based on individual genetic profiles. For instance, the approval of drugs such as QINLOCK (Ripretinib) has revolutionized treatment options for patients with advanced GIST who have not responded to multiple prior therapies. Such targeted therapy specifically addresses a broad spectrum of KIT and PDGFRα mutations, providing effective management for patients previously limited to standard treatments. Additionally, the growing emphasis on biomarker in testing is enhancing patient outcomes by ensuring that individuals receive the most appropriate therapies for their specific tumor profiles. As healthcare providers become more adept at utilizing these advanced treatment modalities, the GIST market is poised for significant expansion, offering new hope for patients battling this challenging condition.

Report Scope and Gastrointestinal Stromal Tumor Market Segmentation         

Gastrointestinal Stromal Tumor Market Definition

Gastrointestinal stromal tumor (GIST) is a type of tumor that originates in the gastrointestinal tract, most commonly in the stomach or small intestine. These tumors arise from interstitial cells of Cajal or precursor cells, which are part of the autonomic nervous system and help regulate gut motility. GISTs are characterized by the presence of specific genetic mutations, often in the KIT or PDGFRA genes, which drive their growth. GISTs are distinct from other gastrointestinal tumors due to their unique histological features and specific treatment options, primarily targeted therapies that inhibit the signaling pathways associated with the mutations.

Gastrointestinal Stromal Tumor Market Dynamics

Drivers

• Increasing Incidence of Gastrointestinal Stromal Tumor

The increasing incidence of gastrointestinal stromal tumors (GISTs) is a crucial driver for market growth, reflecting a significant rise in diagnoses over the years. According to recent studies, GISTs account for approximately 1-3% of all gastrointestinal tumors, with an estimated incidence of 10-20 cases per million people annually. This rising prevalence is largely attributed to enhanced awareness among healthcare providers and patients about GISTs and their symptoms, leading to more frequent diagnostic testing and earlier detection. As a result, the demand for effective treatment options, including targeted therapies like imatinib and sunitinib, is expected to grow significantly. Such growing recognition of GISTs as a distinct clinical entity underscores the importance of advancing treatment options, ultimately driving the gastrointestinal stromal tumor market forward.

• Growing Investment in Research and Development (R&D)

The growing investment in research and development (R&D) for gastrointestinal stromal tumor (GIST) treatments is significantly propelling market expansion. Pharmaceutical companies are increasingly allocating funds towards R&D initiatives, with an estimated global spending of around USD 145 billion in 2022, reflecting a trend toward discovering novel therapies and enhancing existing treatment modalities. Ongoing clinical trials, such as those investigating the efficacy of new targeted therapies and combination treatments, are critical in this effort; for instance, recent studies are exploring the potential of innovative agents such as Ripretinib and Avapritinib, which have shown promise in advanced GIST cases. These investments aim to secure new drug approvals and strive to expand the therapeutic landscape, ultimately leading to improved patient outcomes and prognoses. As a result, the commitment of pharmaceutical companies to advancing GIST treatment options is a key driver in the gastrointestinal stromal tumor market, fostering an environment ripe for innovation and progress in patient care.

Opportunities

• Rise in Emergence of Targeted Therapies

Emerging targeted therapies are significantly transforming the treatment landscape for gastrointestinal stromal tumor (GIST) patients, offering new hope for those who have not responded to existing treatments. Drugs like QINLOCK (Ripretinib) and Avapritinib specifically target genetic mutations, such as KIT and PDGFRA, that drive GIST growth. For instance, QINLOCK is particularly effective for patients who have undergone multiple prior therapies, providing a much-needed option for those with advanced disease. Such shift towards precision medicine enhances the effectiveness of treatment and reduces the likelihood of side effects associated with broader therapeutic approaches. The continued development and approval of such targeted therapies are poised to expand market opportunities, as they improve patient outcomes and increase demand for specialized GIST treatments.

• Increasing Awareness and Diagnosis of GIST

Increased awareness and diagnosis of gastrointestinal stromal tumors (GIST) among healthcare professionals and the general public are critical market opportunities that can lead to earlier detection and improved patient outcomes. As educational initiatives and advocacy efforts highlight the signs and symptoms of GIST, more patients are likely to seek medical attention sooner, facilitating timely interventions. For instance, awareness campaigns led by organizations such as the GIST Support International have empowered both patients and doctors to recognize the symptoms of GIST, which can often be mistaken for other gastrointestinal issues. Early diagnosis can significantly enhance treatment options, including access to targeted therapies that are more effective in the earlier stages of the disease. Consequently, this increase in awareness leads to better patient outcomes and expands the potential market for GIST treatments as more individuals are identified and treated for this rare tumor type.

Restraints/Challenges

• Limited Patient Population

The limited patient population for gastrointestinal stromal tumors (GISTs) presents a significant challenge for the market, as these tumors are classified as rare conditions. This rarity results in a smaller market size, which can deter pharmaceutical companies from investing in research and development for new therapies. For instance, GISTs account for only about 1% of all gastrointestinal tumors, leading to fewer patients participating in clinical trials and a reduced incentive for companies to pursue innovative treatments. This lack of investment can stall the development of potentially life-saving medications, leaving patients with limited options. Consequently, the challenge posed by a limited patient population hampers market growth and restricts access to new and effective therapies for those affected by GIST.

• Significant Expenses Related to Gastrointestinal Stromal Tumor Treatment

High treatment costs pose a significant challenge in the gastrointestinal stromal tumor (GIST) market, particularly for patients who lack adequate insurance coverage. Targeted therapies, such as QINLOCK (Ripretinib) and Avapritinib, while effective, can be prohibitively expensive, often costing thousands of dollars per month. For instance, patients without comprehensive health insurance may struggle to afford these medications, leading to delayed treatment or non-adherence, which can negatively impact their prognosis. This financial burden can deter patients from seeking timely interventions, exacerbating health disparities and leading to poorer health outcomes overall. Consequently, the high costs associated with GIST treatments significantly limit access to care and present a major challenge for the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Gastrointestinal Stromal Tumor Market Scope

The market is segmented on the basis of treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Gastrointestinal Stromal Tumor Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, treatment type, route of administration, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the gastrointestinal stromal tumor (GIST) market, driven by a notable rise in the incidence of this rare cancer. The region's robust demand for targeted therapies reflects a growing preference for personalized treatment options, significantly improving patient outcomes. Additionally, the presence of advanced healthcare facilities equipped with cutting-edge technology further enhances treatment accessibility and effectiveness. This combination of factors positions North America as a dominant force in the GIST market, ensuring continued growth and innovation in therapeutic approaches.

Asia-Pacific region is poised for the highest market growth, fueled by a surge in awareness regarding gastrointestinal stromal tumors (GISTs) and their associated treatment options. As educational initiatives and healthcare campaigns spread, more individuals are recognizing the importance of early diagnosis and timely intervention. Additionally, the rapid rise in disposable income among the population is enabling greater access to advanced healthcare services and targeted therapies. This combination of heightened awareness and improved economic conditions positions Asia-Pacific as a significant player in the GIST market, driving demand for innovative treatment solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Gastrointestinal Stromal Tumor Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Gastrointestinal Stromal Tumor Market Leaders Operating in the Market Are:

• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Blueprint Medicines Corporation (U.S.)
• NATCO Pharma Limited (India)

Latest Developments in Gastrointestinal Stromal Tumor Market

• In August 2024, Kura Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to advancing precision medicines for cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ziftomenib. This powerful and selective menin inhibitor is being developed for the treatment of advanced gastrointestinal stromal tumors (GIST)
• En septembre 2021, Zai Lab, une société biopharmaceutique innovante en phase commerciale, a annoncé que la Food and Drug Administration de Taïwan avait approuvé sa demande de nouveau médicament (NDA) pour QINLOCK (Ripretinib) pour traiter les patients adultes atteints de tumeurs stromales gastro-intestinales avancées (GIST) qui ont déjà été traités avec trois inhibiteurs de kinase ou plus, dont l'imatinib. QINLOCK cible spécifiquement la large gamme de mutations KIT et PDGFRα associées à la progression des GIST
• En mai 2020, la Food and Drug Administration américaine a approuvé les comprimés de Qinlock (Ripretinib), le désignant comme le premier nouveau médicament spécifiquement autorisé comme traitement de quatrième intention pour les tumeurs stromales gastro-intestinales avancées (GIST), qui sont des tumeurs qui se développent dans le tractus gastro-intestinal. Qinlock est destiné aux patients adultes qui ont déjà subi un traitement avec trois thérapies ou plus par inhibiteur de kinase, y compris l'imatinib

SKU-54246